Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose luspatercept (Revlodil) administration in healthy adult male volunteers for anti-doping sample method evaluation
jRCT1031250476Active, not recruiting
- Sponsor
- Japan Anti-Doping Agency
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of luspatercept, sponsored by Japan Anti-Doping Agency. Primary endpoint: Effects of sample collection method. Started Sep 2025; status: active, not recruiting.
02
Drugs
luspatercept
Beyond the preview
Go deeper on jRCT1031250476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250476.